Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $37.83M fell 22.9% year over year, ahead of the -23.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 17.8% from the prior quarter. Over 3 fiscal years it compounded at -49.6% a year.

Context

  • Selling, general & admin amounted to 107.7% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $169.96M (-7.3%) for the fiscal year ending Dec 2026, a step up from the -25.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.83M-17.8% QoQ
Last fiscal yearDec 2025
$183.29M-25.5% YoY
LTMMar 2026
$172.08M-23.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.9%+4.9%+27.7 pp
1 year-25.5%-7.3%+18.3 pp
3-year CAGR-49.6%-1.6%+48.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
183.29M USD
Year-over-year change
-25.5%
4-year CAGR
-32.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -23.5% is the 7th highest of 8, against a peer median of -3.3%.
  • Selling, general & admin amounts to 121.8% of revenue for DNA, versus a peer median of 69.5%.
DNA Competitors
Selling, General & Admin for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$172.08M USD-23.5%-49.6%121.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$153.2M USD-3.3%+13.5%40.4%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$152.74M USD-3.6%+9.9%73.2%
ARVNArvinas, Inc.LTM Mar 2026$86.5M USD-47.9%+3.9%96.8%
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
REPLReplimune Group, Inc.LTM Dec 2025$69.65M USD———
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M USD——105.6%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$59.07M USD+263.5%+71.2%—
MGTXMeiraGTx Holdings plcLTM Mar 2026$52.46M USD-2.3%+4.4%65.8%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M USD+59.1%+55.2%—
Peer median (excluding DNA) —-3.3%+9.9%69.5%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.